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Background: The sleeve gastrectomy is a surgical technique to treat morbid obesity by both restrictive
and probably hormonal action. Originally developed as a ﬁrst stage to gastric bypass, it is more and more
performed as a sole procedure. Therefore it is important to report results on weight loss and reduction in
co-morbidity.
Methods: A consecutive series of 74 morbid obese patients were evaluated. Parameters were operative
variables, complications, weight loss and the need for medication for co-morbidity at least six months
postoperatively.
Results: Six procedures included the removal of a band and twice a vertical banded gastroplasty was
performed previously. Median operating time diminished over time to 71 min. Three procedures were
converted into open approach. Major complications were rhabdomyolysis (2), bleeding (2) and leakage
(4). Four days was the mean hospital stay. The median follow-up was 12 months (range 6e33). The
median percentage of excess weight loss was 49.6% (range 22e96%EWL). The median loss in BMI points
was 23.1% (range 9e50%BMIL). Three quarters of the patients were able to diminish or stop their
medication for diabetes, hypertension and hyperlipedemia.
Conclusion: The laparoscopic gastric sleeve is effective in reduction of both weight and co-morbidity and
has potential as a sole procedure. Patient’s selection is, however, recommendable for initial surgical
experience and longer follow-up will be necessary.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The sleeve gastrectomy is a surgical technique to treat morbid
obesity.1 This technique is a mainly restrictive procedure designed
to decrease appetite by reducing the ability of the stomach to
distend and producing the sensation of fullness with minimal oral
intake. The surplus value probably lies in the interference with the
digestive hormonal structure. Since its introduction, the indication
has broadened from the ﬁrst step in treatment of the super obese
to a single procedure for a wider range of patients suffering from
obesity.2e4 As this appeared only recently, it is difﬁcult to compete
with the long-term results of alternative techniques such as the
laparoscopic adjustable gastric band and gastric bypass. As the
sleeve gastrectomie is theoretically a more deﬁnite procedure
than the band without the disadvantages of malabsorptive bypass
and the initial results reported are promising, it is necessary to
report results on weight loss and co-morbidity. Therefore we
evaluated our results of the laparoscopic sleeve gastrectomy.uijs).
ciates Ltd. Published by Elsevier Lt2. Methods
2.1. Patients
The bariatric surgery section of a large non-academic institute
initially adapted the sleeve gastrectomy as a ﬁrst step-procedure.
Since August 2006 it has been performed as a stand-alone proce-
dure. The laparoscopic sleeve gastrectomy was performed on the
patients’ request or as an escape procedure in case a gastric bypass
was too demanding. From this moment on, all patients who
underwent a laparoscopic sleeve gastrectomy for treatment of
morbid obesity and with a minimum of 6 months follow-up were
enrolled into this study.2.2. Assessment
Medical charts were reviewed for patients’ characteristics,
co-morbidity and prescribed medications, operative parameters,
length of hospital stay and postoperative complications. Patients
are followed at the outpatients department at 1, 6 and 12 months
postoperatively and then annually. An additional check-up by
a research nurse for all patients was performed by the end of April
2009. Gathered data were weight, ability to take solid food,d. All rights reserved.
Table 2
Duration of procedure.
Time in minutes Median Range P-value
First 25 cases 110 63e248 .000a
Middle 24 cases 82 53e191 .007a
Last 25 cases 71 43e117 .081b
a Wilcoxon Test, compared to last 25 cases.
b Wilcoxon Test, compared to ﬁrst 25 cases.
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from not to very in 4 steps, co-morbidity and differences in
prescribed medications. The co-morbidity was deﬁned as a condi-
tion for which medical treatment was prescribed.
2.3. Surgical procedure
The patient is positioned anti-Trendelenburg on a special widen
and extended surgical table with both arms away from the body.
After an established pneumoperitoneum 5 ports are introduced
into the abdominal cavity, sometimes the one on the lateral right
side can be omitted. The abdomen is explored and liver retracted
through the subxphoidal position. One gauze is used to remain the
omentum laterally and facilitate the exposure of the angle of His.
Dissection of this angle is by coagulation. Then the bursa is opened
at the point of the ﬂexura lienalis at which point it is safe and easy
(less adhesions to pancreas). Using the 10 mm LigaSure (Covidien),
the omentum is separated close to the greater curvature both
proximally to the angle of His and distally till approximately 6 cm’s
prepyloric. This point is usually marked by some adhesions on the
dorsal side of the stomach and ventrally by small veins in a so-
called crows’feet shape. Guided by a 34-Fr tube, the stomach is
divided using 60 mm EndoGia cartridges (Covidien). It takes nor-
mally two green (4.8 mm) staplelines followed by three to ﬁve blue
(3.5 mm) ones. Intraoperative leak tests were not performed. In
case of a staple line bleeding an Endoclip (Covidien) is used to clip
the bleeding point. In case of less visibility of the angle of His
initially, the separation of the omentum proximally and dissection
of the stomach are alternated. The dissected part is extracted
through the 15 mm trocar site which is closed with endosutures
using Endoclose (Covidien). Haemostasis is followed by extraction
of the gauze. Then the ports are removed under visibility to prevent
abdominal wall bleeding.
2.4. Analysis
The statistical software used was SPSS Statistics 17.0 in order to
apply Pearson’s Chi-square test, Fisher’s Exact Test for ordinal data.
Spearman correlations were employed to analyse relationships
between subgroups. The Wilcoxon test was used to analyse
nominal data. A p-value below .05 was considered signiﬁcant.
3. Results
A total of 74 patients was included. The male/female ration was
29:45 and their characteristics are outlined in Table 1.
The median duration of the procedure was 89 min (range
43e248). There was a signiﬁcant declining trend in time. See Table
2. Concomitant procedures were 6 removals of a band, two
conversions from a vertical banded gastroplasty, two cholecystec-
tomies and one perianal ﬁstula procedure. The median length of
hospital stay was 4 days (range 2e126).
Sixteen patients had postoperative complications with a total of
20 events including three conversions to an open procedure. Of theTable 1
Patients characteristics.
Median Range
Age, y 42 16e66
Weight, kg 155 92e255
BMI, kg/m2 51 35e94
Waist size, cm 147 118e210
Hip size, cm 148 110e220
BMI ¼ Body Mass Index.8 patients with a previous procedure, 4 encountered at least one
complication. It is more than compared to a complication rate of 18
per cent with the primary procedures. (not signiﬁcant, Fisher’s
Exact Test p ¼ .061). Four times a leakage was encountered. One
managed by the radiologist with percutaneous drainage, the other
three with surgical drainage. Following subsequent conservative
treatment, all four ﬁstulas dried up. Other major complications
were rhabdomyolysis (2) and re-intervention for bleeding (2).
Minor complications included delayed gastric emptying (3), wound
infection (2), an atrial ﬂutter, one incisional hernia, one sub-
phrenical abscesses (conservatively treated) and one wound
haematoma.
The median postoperative follow-up was 12 months (range
6e33). Fifty-ﬁve patients were able to eat solid food, 18 rated this
ability as reasonable and one patient was still on ﬂuid food. The
follow-up time of the latter 19 patients was shorter. Overall, 69
patients scored very satisﬁed on a verbal descriptor scale. The
portion of dissatisfactionwas not related to any other outcome such
as complications. The percentage of excess weight loss was median
49.6% (range 22e96%EWL). The loss in BMI points was median
23.1% (range 9e50%BMIL). The differences in medical treatment for
co-morbidity is outlined in Table 3. Forty-ﬁve times out of 60 (75%),
patients were able to diminish or stop their medications diabetes,
hypertension and hyperlipedemia.
4. Discussion
The results of this study underlined that the laparoscopic sleeve
gastrectomy is an effective procedure in reducing weight. With
regard to operating time and convalescence it is a feasible tech-
nique. Most important was the focus on co-morbidity and clinical
relevant was the reduction or quitting of medication in 75% of the
cases.
It has been stated before that laparoscopic sleeve gastrectomy is
a less technically demanding procedure than laparoscopic gastric
bypass. Nevertheless, a learning curve for even experienced bari-
atric surgeons was observed: median operating time decreased
from 110 to 71 min. The technique in the present study was
somewhat different than described in other reports.5e7 First, no
specimen collection bag was used. It is not likely that the technique
will be adjusted on this point as in the evaluation there was an
infection rate of only 2.7%. Secondly, the stapler line was not
routinely over-sewn. This is probably associatedwith bleedings and











T2DM (oral) 9 1 1 7 .000
T2DM (insulin) 11 1 7 3 .000
HT 26 8 7 11 .000
HL 14 5 4 5 .000
T2DM ¼ Type 2 Diabetes Mellitus, (oral) ¼ oral medication, HT ¼ Hypertension,
HL ¼ hyperlipedemia, Pearson’s Chi-square test.
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drainage were due to this complication (5.4%). The total number of
leakageswas too small for further investigation. In the study of Fuks
et al.8 with a comparable design, a gastric leakage was encountered
in 5.1%. Although higher incidences than reported in studies
wherein over-sewing was used,5e7 also no leakage has been
reported in a trial without over-sewing.9 Within all these trials
there is no distinctive difference in bleeding rate. As for haemo-
stasis, the use of an endoclip or a suture when indicated seemed to
be an acceptable alternative for over-sewing routinely. The local-
isation of a bleeding intra-operatively was mostly distally and
visible after removal of the gastric tube under vision. Then an
endoclip was used. The postoperative bleedings were mostly from
the vasa breva area. There were no mortalities. The total number of
complications was somewhat disappointing and responsible for
prolonged hospital stays up to 126 days. As 15 out of 20 compli-
cations were following the ﬁrst 17 procedures performed, it was
presumed related to initial experience and initial heavier patients.
Although not signiﬁcant, there was a high impact of previous
gastric banding on complications. Based on these experience the
protocol has been changed into removal of a gastric band and
performing the subsequent sleeve gastrectomy at least 12 weeks
later. The severe complication of rhabdomyolysis was encountered
twice. This has been reported before.10e12 Supposedly after opti-
mizing the anaesthetic technique for ﬂuid control, this complica-
tion has not been encountered anymore. Almost all complications
in the last year were delayed gastric emptying requiring
re-hospitalisation.
The percentage of excess weight loss was median 49.6%. Even
though the measure moment was not ﬁxed and follow-up ranged
from 6 to 33months, this result was comparable to the percentages
reported in the literature. The other important endpoint was
reduction of medicaments necessary for an obesity related chronic
condition. The inﬂuence on co-morbidity is the most important
endpoint in bariatric studies. Vidal et al.13 reported the diabetes and
metabolic syndrome reduction in severely obese patients. They
reported a comparable effectiveness for this speciﬁc group for
sleeve gastrectomy as well as gastric bypass. In the study of
DePaula14 promising results were reported for the laparoscopic
interposition of an ileum segment into the proximal jejunum. In
one study thirty patients with diabetes were treated by LSG and
there was a resolution of 63% at 6 months follow-up.15 In this study
medical treatment for diabetes, hypertension or hyperlipidemia
was noted for 60 patients. 32% of this group could lower their dose
and 43% stopped at all. The number of resolution is lower compared
to most ﬁgures in a systematic review comparing gastric banding
and bypass.16
In summary, the laparoscopic sleeve gastrectomie is effective in
reduction of weight and co-morbidity. When the complication rate
decreases with experience, it can be regarded as a safe technique.
Therefore, patient’s selection is recommendable for initial surgical
experience. With a shorter operative time and less postoperative
complications it has the possibilities to replace the gastric bypass as
the standard treatment for patients suffering from morbid obesity.
Supposedly, more beneﬁts could be revealed as a result foodfollows the physiological route. Furthermore, the possibility
remains available to convert a sleeve gastrectomie into a gastric
bypass in cases of weight reducing failures. On the other hand, the
present results were only of short term nature and other long
follow-up data are lacking yet, there are possibilities of regaining
weight after a sleeve gastrectomy, dilatation of the pouch and
complications following re-intervention. So, the gastric bypass
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